FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Medical Devices

FDA Clears Royal Philips Wearable Light Therapy

FDA clears a Royal Philips 510(k) for the Philips BlueControl wearable light therapy device to treat mild psoriasis.

Human Drugs

FDA Panel Backs Novartis CAR-T Cell Therapy

FDAs Oncologic Drugs Advisory Committee unanimously votes to support approval of a Novartis BLA for CTL019 (tisagenlecleucel-T), a chimeric antigen re...

Human Drugs

FDA Issues May Hinder Anti-abuse Opioids: Tufts

A Tufts Center for the Study of Drug Development panel of experts says that a lack of consistent FDA regulatory policy can hinder development of abuse...

Human Drugs

Pfizer Xeljanz sNDA Accepted for Ulcerative Colitis

FDA accepts for review a Pfizer supplemental NDA for Xeljanz (tofacitinib citrate) for treating adult patients with moderately to severely active ulce...

FDA General

Trump Renews Call to Double Industry User Fees

The Trump Administration renews its call for Congress to double user fees paid by industry to help with the governments budget.

Human Drugs

FDA Clears TechLab Tri-Combo Parasite Screen

FDA clears a TechLab 510(k) for the Tri-Combo Parasite Screen test for detecting Giardia, Cryptosporidium, and Entamoeba histolytica, the three most c...

Human Drugs

FDA Orphan Status for Allena Pharma Drug

FDA grants Allena Pharmaceuticals an orphan drug designation for ALLN-177, an oral formulation of oxalate decarboxylase for treating primary hyperoxal...

Medical Devices

FDA Releases Magellan Diagnostics FDA-483

FDA releases an FDA-483 with nine inspection observations from its inspection at Magellan Diagnostics, the subject of an agency warning about potentia...

Human Drugs

FDA Wants Comments on Generic Guidances

FDA solicits comments on new and revised product-specific guidances for developing generic drugs.

Human Drugs

Public Citizen Wants IV Solution Banned

Public Citizen petitions FDA to withdraw hydroxyethyl starch solutions from the market due to their risks and the availability of safer alternatives.